GRFS

Grifols 2023 Annual Report on Form 20-F filed with the SEC

Retrieved on: 
Friday, April 19, 2024
GRFS, International, Sustainability, Annual report, Class, American depositary receipt, MD, EUR, Risk management, International Financial Reporting Standards, Bank statement, MCE, GRF, Growth

Grifols' annual report on Form 20-F provides investors with an overview of the company's governance practices, including information about the Board of Directors and its committees, executive compensation, and risk management.

Key Points: 
  • Grifols' annual report on Form 20-F provides investors with an overview of the company's governance practices, including information about the Board of Directors and its committees, executive compensation, and risk management.
  • Grifols' ordinary shares (Class A) are listed on the Spanish stock market and form part of the IBEX-35 (GRF).
  • Grifols will deliver, within a reasonable time after request, a hard copy of the annual report on Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request.
  • To request a hard copy, shareholders may contact Grifols by email at [email protected] to the attention of Grifols' Investor Relations & Sustainability, Re: 2023 Annual Report on Form 20-F.

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Retrieved on: 
Thursday, April 4, 2024
Certification, Plasma, CE, GRFS, Risk, Arbovirus, Climate, RNA, GRF, Fever Dream, IVDR, Chikungunya, Death, Dengue virus, MCE, Blood bank, NAT, Vertically transmitted infection, Medical device

These are the four most significant arboviruses of concern, all spread through mosquito vectors.

Key Points: 
  • These are the four most significant arboviruses of concern, all spread through mosquito vectors.
  • With the dengue virus alone, there were more than 5 million cases and 5,000 deaths reported globally in 2023.1
    Further strengthening the Grifols Procleix portfolio for blood donor screening, the Procleix ArboPlex Assay uses plasma or serum samples to detect arboviral RNA.
  • Blood banks and collection centers could decide that deferrals are unnecessary if donors were tested and found negative using the Procleix ArboPlex Assay.
  • “With its 4-in-1 arbovirus test feature, the Grifols Procleix ArboPlex Assay has the ability to speed up and overall improve donor screening laboratory efficiency,” said Antonio Martínez, president of Grifols Diagnostic Business Unit.

Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman

Retrieved on: 
Friday, March 29, 2024
Research, Communication, FY, GRFS, SAN, Person, Disclosure, American depositary receipt, Annual report, Hagens Berman

SAN FRANCISCO, March 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
  • Grifols S.A. (GRFS – ADR ADR Class B) Investigation:
    Shares in embattled Spanish pharmaceutical and chemical manufacturer Grifols S.A. declined sharply again on Mar.
  • Gotham’s latest report takes issue with Grifols’ disclosure of a 319 million euro ($346.6 million) loan in its 2022 Annual Report.
  • 5, 2024, securities analysts at Alantra Equities downgraded Grifols shares, reporting saying it had “lost confidence” in the company.

Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman

Retrieved on: 
Monday, March 25, 2024
Research, Communication, FY, GRFS, SAN, Person, Disclosure, American depositary receipt, Annual report, Hagens Berman, Life insurance

SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
  • Grifols S.A. (GRFS – ADR ADR Class B) Investigation:
    Shares in embattled Spanish pharmaceutical and chemical manufacturer Grifols S.A. declined sharply again on Mar.
  • Gotham’s latest report takes issue with Grifols’ disclosure of a 319 million euro ($346.6 million) loan in its 2022 Annual Report.
  • 5, 2024, securities analysts at Alantra Equities downgraded Grifols shares, reporting saying it had “lost confidence” in the company.

Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman

Retrieved on: 
Wednesday, March 20, 2024
Research, Communication, FY, GRFS, SAN, Person, Disclosure, American depositary receipt, Annual report, Hagens Berman, Cryptocurrency

SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
  • Grifols S.A. (GRFS – ADR ADR Class B) Investigation:
    Shares in embattled Spanish pharmaceutical and chemical manufacturer Grifols S.A. declined sharply again on Mar.
  • Gotham’s latest report takes issue with Grifols’ disclosure of a 319 million euro ($346.6 million) loan in its 2022 Annual Report.
  • 5, 2024, securities analysts at Alantra Equities downgraded Grifols shares, reporting saying it had “lost confidence” in the company.

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Retrieved on: 
Wednesday, February 14, 2024
Acquisition, Liver, Bleeding, MCE, USD, SCAP, Immunoglobulin M, FC, Fibrinogen, Wound healing, Standard of care, Fibrin, Risk, Safety, Immunoglobulin G, Element, GRFS, Medicine, Patient, Immunoglobulin A, AFD, Clinical trial, Protein, GRF, Plasma, Factor, CAP, Community-acquired pneumonia, Pharmaceutical industry

AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.

Key Points: 
  • AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.
  • Fibrinogen, a plasma protein produced in the liver, plays a key role in stopping blood loss and in wound healing.
  • “The positive results for Biotest’s fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” said Victor Grifols Deu, Grifols Chief Operating Officer.
  • The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as the company’s pipeline and sales presence.

Analyst Downgrades Grifols S.A. (GRFS) After Recent Short Seller Report – Hagens Berman

Retrieved on: 
Monday, February 12, 2024
BPC, GRF, Hagens Berman, Research, Person, GRFS

Securities analyst Juan Ros-Padilla of Oddo BHF recently issued a note to clients, downgrading Grifols shares to “underperform” and halving his price target to €9.

Key Points: 
  • Securities analyst Juan Ros-Padilla of Oddo BHF recently issued a note to clients, downgrading Grifols shares to “underperform” and halving his price target to €9.
  • “We see few incentives for the mainstream institutions to hold a controversial and highly levered stock,” Ros-Padilla reportedly said.
  • The analyst downgrade comes in the wake of a scathing Jan. 9, 2024 short seller report attacking the company’s accounting and corporate governance that has sent Grifols’ shares reeling.
  • In a report entitled “Grifols S.A.: Scranton and the Undisclosed Debts.

Analyst Downgrades Grifols S.A. (GRFS) After Recent Short Seller Report – Hagens Berman

Retrieved on: 
Thursday, February 8, 2024
SAN, Hagens Berman, Person, Research, GRFS, BPC, GRF

SAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Grifols, S.A. (NASDAQ: GRFS) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Grifols, S.A. (NASDAQ: GRFS) investors who suffered substantial losses to submit your losses now .
  • Securities analyst Juan Ros-Padilla of Oddo BHF recently issued a note to clients, downgrading Grifols shares to “underperform” and halving his price target to €9.
  • “We see few incentives for the mainstream institutions to hold a controversial and highly levered stock,” Ros-Padilla reportedly said.
  • The analyst downgrade comes in the wake of a scathing Jan. 9, 2024 short seller report attacking the company’s accounting and corporate governance that has sent Grifols’ shares reeling.

Analyst Downgrades Grifols S.A. (GRFS) After Recent Short Seller Report – Hagens Berman

Retrieved on: 
Thursday, February 1, 2024
Hagens Berman, SAN, Person, Research, BPC, GRF, GRFS

SAN FRANCISCO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Grifols, S.A. (NASDAQ: GRFS) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Grifols, S.A. (NASDAQ: GRFS) investors who suffered substantial losses to submit your losses now .
  • Securities analyst Juan Ros-Padilla of Oddo BHF recently issued a note to clients, downgrading Grifols shares to “underperform” and halving his price target to €9.
  • “We see few incentives for the mainstream institutions to hold a controversial and highly levered stock,” Ros-Padilla reportedly said.
  • The analyst downgrade comes in the wake of a scathing Jan. 9, 2024 short seller report attacking the company’s accounting and corporate governance that has sent Grifols’ shares reeling.

Analyst Downgrades Grifols S.A. (GRFS) After Recent Short Seller Report – Hagens Berman

Retrieved on: 
Thursday, January 25, 2024
GRF, SAN, BPC, Hagens Berman, Person, GRFS, Research, Cryptocurrency

SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Grifols, S.A. (NASDAQ: GRFS) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Grifols, S.A. (NASDAQ: GRFS) investors who suffered substantial losses to submit your losses now .
  • Securities analyst Juan Ros-Padilla of Oddo BHF recently issued a note to clients, downgrading Grifols shares to “underperform” and halving his price target to €9.
  • “We see few incentives for the mainstream institutions to hold a controversial and highly levered stock,” Ros-Padilla reportedly said.
  • The analyst downgrade comes in the wake of a scathing Jan. 9, 2024 short seller report attacking the company’s accounting and corporate governance that has sent Grifols’ shares reeling.